The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use. MONTREAL, Feb. 16The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use. MONTREAL, Feb. 16

Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany

2026/02/16 20:30
5 min di lettura
Per feedback o dubbi su questo contenuto, contattateci all'indirizzo [email protected].
  • The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use.

MONTREAL, Feb. 16, 2026 /PRNewswire/ – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex Biologics (Cordex), announced that Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, has been granted Status 1 listing by the NUB (Neue Untersuchungs- und Behandlungsmethoden) program in Germany.

The NUB designation is a recognition that Zemcelpro® (dorocubicel) is supported by a relevant and growing body of clinical evidence and enables hospitals to immediately apply for temporary, supplementary reimbursement for its use while broader reimbursement pathways continue to be evaluated.  Notably, 220 hospitals across Germany have expressed interest in accessing Zemcelpro® (dorocubicel) through the NUB mechanism for the 2026 calendar year.

“NUB Status 1 represents a significant milestone for ExCellThera and Cordex and reflects both the innovative nature of Zemcelpro® (dorocubicel) and its benefit in in addressing a pressing unmet medical need in allogeneic haematopoietic stem cell transplantation,” said David Millette, CEO of ExCellThera. “Under its initial label, Zemcelpro® (dorocubicel) is indicated for patients with life threatening blood cancers who have limited therapeutic options.”

Zemcelpro® (dorocubicel) has recently received conditional marketing authorization from the European Commission for the treatment of adults with haematological malignancies requiring allogeneic haematopoietic stem cell transplantation following myeloablative conditioning, for whom no other suitable donor cells are available.

With NUB status 1 in place for Zemcelpro® (dorocubicel), Cordex will work closely with leading German stem cell transplant centers to support individual NUB applications and to further expand clinical adoption. In parallel, the company will invest in post-market registry participation, and in evidence and economic data generation to support longer-term reimbursement and inclusion of Zemcelpro® (dorocubicel) in clinical guidelines. Together, these elements strengthen Zemcelpro® (dorocubicel)’s commercial foundation in Germany and provide a constructive bridge toward future statutory reimbursement by the healthcare system.

The availability of Zemcelpro® (dorocubicel) in individual European countries depends on several factors, including completion of national reimbursement procedures. In the interim, Cordex will engage with national health authorities to enable early access for eligible patients and is engaging with leading stem cell transplantation centres to establish a future network of treatment sites for Zemcelpro® (dorocubicel) administration.

Additional regulatory filings are planned for Zemcelpro® (dorocubicel) with other health authorities, including in the US, Canada, the UK, and Switzerland.

Cordex is also actively seeking strategic partnerships to support and accelerate the commercialization of Zemcelpro® (dorocubicel) in Europe and other international markets.

About Zemcelpro®

Zemcelpro®, also known as UM171 Cell Therapy, is a novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit.  

Zemcelpro® (dorocubicel), developed by Cordex, a wholly owned subsidiary of ExCellThera, has been evaluated in 120 patients with haematologic malignancies in clinical trials in the United States, Europe and Canada. Zemcelpro® (dorocubicel) has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designations from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA.

Zemcelpro® (dorocubicel) has been tested in Phase 2 trials in patients with high and very high-risk acute leukemias and myelodysplasias who have limited treatment options with low survival outcomes and high incidence of relapse under the current standard of care, including patients with patients with TP53 mutations or other genetic abnormalities, patients requiring a second transplant, and patients with refractory or active disease. A pivotal Phase 3 trial in this patient population will be initiated as soon as possible.

The use of Zemcelpro® (dorocubicel) in other patient populations, including pediatric patients and patients with non-malignant haematological diseases, is also being investigated.

For complete product information, including Warnings and Precautions for Use and Adverse Reactions (and their appropriate management), please refer to the EU Summary of Product Characteristics (SmPC) for Zemcelpro®.

The product safety and efficacy have not yet been established by other regulatory agencies, such as the U.S. FDA, the MHRA and Health Canada.

About ExCellThera and UM171 Technology

ExCellThera is a world leader in enhanced blood stem cell therapies. ExCellThera’s proprietary EnhanceTM platform for cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including the proprietary molecule UM171 which has a first-in-class mechanism of action for ex vivo expansion and metabolic fitness of HSCs. For additional information, visit excellthera.com, and follow us on LinkedIn.

Zemcelpro® is a registered trademark of ExCellThera or its related companies.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zemcelpro-dorocubicel-receives-nub-status-1-in-germany-302688424.html

SOURCE ExCellThera

Opportunità di mercato
Logo nubcat
Valore nubcat (NUB)
$0.00287
$0.00287$0.00287
+7.49%
USD
Grafico dei prezzi in tempo reale di nubcat (NUB)
Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta [email protected] per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.

Potrebbe anche piacerti

Let insiders trade – Blockworks

Let insiders trade – Blockworks

The post Let insiders trade – Blockworks appeared on BitcoinEthereumNews.com. This is a segment from The Breakdown newsletter. To read more editions, subscribe ​​“The most valuable commodity I know of is information.” — Gordon Gekko, Wall Street Ten months ago, FBI agents raided Shayne Coplan’s Manhattan apartment, ostensibly in search of evidence that the prediction market he founded, Polymarket, had illegally allowed US residents to place bets on the US election. Two weeks ago, the CFTC gave Polymarket the green light to allow those very same US residents to place bets on whatever they like. This is quite the turn of events — and it’s not just about elections or politics. With its US government seal of approval in hand, Polymarket is reportedly raising capital at a valuation of $9 billion — a reflection of the growing belief that prediction markets will be used for much more than betting on elections once every four years. Instead, proponents say prediction markets can provide a real service to the world by providing it with better information about nearly everything. I think they might, too — but only if insiders are free to participate. Yesterday, for example, Polymarket announced new betting markets on company earnings reports, with a promise that it would improve the information that investors have to work with.  Instead of waiting three months to find out how a company is faring, investors could simply watch the odds on Polymarket.  If the probability of an earnings beat is rising, for example, investors would know at a glance that things are going well. But that will only happen if enough of the people betting actually know how things are going. Relying on the wisdom of crowds to magically discern how a business is doing won’t add much incremental knowledge to the world; everyone’s guesses are unlikely to average out to the truth. If…
Condividi
BitcoinEthereumNews2025/09/18 05:16
Tether CEO Delivers Rare Bitcoin Price Comment

Tether CEO Delivers Rare Bitcoin Price Comment

Bitcoin price receives rare acknowledgement from Tether CEO Ardoino
Condividi
Coinstats2025/09/17 23:39
Cloud mining is gaining popularity around the world. LgMining’s efficient cloud mining platform helps you easily deploy digital assets and lead a new wave of crypto wealth.

Cloud mining is gaining popularity around the world. LgMining’s efficient cloud mining platform helps you easily deploy digital assets and lead a new wave of crypto wealth.

The post Cloud mining is gaining popularity around the world. LgMining’s efficient cloud mining platform helps you easily deploy digital assets and lead a new wave of crypto wealth. appeared on BitcoinEthereumNews.com. SPONSORED POST* As the cryptocurrency market continues its recovery, Ethereum has once again become the center of attention for investors. Recently, the well-known crypto mining platform LgMining predicted that Ethereum may surpass its previous all-time high and surge past $5,000. In light of this rare market opportunity, choosing a high-efficiency, secure, and low-cost mining platform has become the top priority for many investors. With its cutting-edge hardware, intelligent technology, and low-cost renewable energy advantages, LgMining Cloud Mining is rapidly emerging as a leader in the cloud mining industry. Ethereum: The Driving Force of the Crypto Market Ethereum is not only the second-largest cryptocurrency by market capitalization but also the backbone of the blockchain smart contract ecosystem. From DeFi (Decentralized Finance) to NFTs (Non-Fungible Tokens) and the broader Web3.0 infrastructure, most innovations are built on Ethereum. This widespread utility gives Ethereum tremendous growth potential. With the upcoming scalability upgrades, the Ethereum network is expected to offer improved performance and transaction speed—likely triggering a fresh wave of market enthusiasm. According to the LgMining research team, Ethereum’s share among institutional and retail investors continues to grow. Combined with shifting monetary policies and global economic uncertainties, Ethereum is expected to break past its previous high of over $4,000 and aim for $5,000 or more in the coming months. LgMining Cloud Mining: Unlocking a Low-Barrier Path to Wealth Traditional crypto mining often requires expensive mining rigs, stable electricity, and complex maintenance—making it inaccessible for the average person. LgMining Cloud Mining breaks down these barriers, allowing anyone to easily participate in mining Ethereum and Bitcoin without owning hardware. LgMining builds its robust and efficient mining infrastructure around three core advantages: 1. High-End Equipment LgMining uses top-tier mining hardware with exceptional computing power and reliability. The platform’s ASIC and GPU miners are carefully selected and tested to…
Condividi
BitcoinEthereumNews2025/09/18 03:04